M&A Deal Summary |
|
|---|---|
| Date | 2025-06-23 |
| Target | PHX Minerals |
| Sector | Oil/Gas Exploration |
| Buyer(s) | Whitehawk Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 18 |
| Revenue | 26M USD (2024) |
Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Whitehawk Therapeutics was founded in 2007 and is headquartered in Morristown, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Oil/Gas Exploration M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Oklahoma M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-03-26 |
Aadi Sub
United States Aadi Sub provides sirolimus protein-bound particles for injectable suspension) (albumin-bound) business. |
Sell | $100M |
